Resources from the same session
2714 - Sitravatinib demonstrates activity in patients with novel genetic alterations that inactivate CBL
Presenter: Lyudmila Bazhenova
Session: Proffered paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1971 - Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach
Presenter: Ulrik Lassen
Session: Proffered paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
5033 - Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive (NTRK-fp) Tumors: Pooled Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: George Demetri
Session: Proffered paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
5879 - First-in-Human, First-in-Class study of the CD44v6 inhibitor AMC303 as monotherapy in patients with advanced epithelial tumors
Presenter: Emiliano Calvo
Session: Proffered paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1429 - Initial results from a phase 1/2a trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer
Presenter: John Hilton
Session: Proffered paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Proffered paper session - Developmental therapeutics - Invited Discussant 410O and 411O
Presenter: Udai Banerji
Session: Proffered paper session - Developmental therapeutics
Resources:
Slides
Webcast